Terry-Ann Burrell - 12 Jul 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
12 Jul 2023
Net transactions value
-$1,412,414
Form type
4
Filing time
14 Jul 2023, 18:52:12 UTC
Previous filing
21 Jun 2023
Next filing
02 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale $273,400 -24,302 -14% $11.25 147,545 12 Jul 2023 Direct F1, F2
transaction RXRX Class A Common Stock Sale $948,289 -78,071 -53% $12.15 69,474 12 Jul 2023 Direct F1, F3
transaction RXRX Class A Common Stock Sale $42,124 -3,195 -4.6% $13.18 66,279 12 Jul 2023 Direct F1, F4
transaction RXRX Class A Common Stock Sale $44,457 -3,157 -4.8% $14.08 63,122 12 Jul 2023 Direct F1, F5
transaction RXRX Class A Common Stock Sale $104,143 -8,275 -13% $12.59 54,847 13 Jul 2023 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.60 to $11.59 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F3 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.60 to $12.54 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F4 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.76 to $13.72 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F5 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $13.81 to $14.56 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F6 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.105 to $12.98 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.